Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Operating Leases (2022 - 2025)

Cytek Biosciences (CTKB) has disclosed Operating Leases for 3 consecutive years, with $11.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Leases rose 19.3% year-over-year to $11.3 million, compared with a TTM value of $11.3 million through Dec 2024, up 19.3%, and an annual FY2024 reading of $11.3 million, up 19.3% over the prior year.
  • Operating Leases was $11.3 million for Q4 2024 at Cytek Biosciences, up from $9.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $13.0 million in Q3 2023 and bottomed at $9.5 million in Q4 2023.
  • Average Operating Leases over 3 years is $11.7 million, with a median of $12.3 million recorded in 2022.
  • The sharpest move saw Operating Leases dropped 23.01% in 2023, then increased 19.3% in 2024.
  • Year by year, Operating Leases stood at $12.3 million in 2022, then decreased by 23.01% to $9.5 million in 2023, then grew by 19.3% to $11.3 million in 2024.
  • Business Quant data shows Operating Leases for CTKB at $11.3 million in Q4 2024, $9.5 million in Q4 2023, and $13.0 million in Q3 2023.